Premium
Comparison of the effects of Mylabris and Acanthopanax senticosus on promising cancer marker polyamines in plasma of a Hepatoma‐22 mouse model using HPLC‐ESI‐MS
Author(s) -
Wang Qian,
Wang Yixiang,
Liu Ran,
Yan Xu,
Li Yujiao,
Fu Hui,
Bi Kaishun,
Li Qing
Publication year - 2013
Publication title -
biomedical chromatography
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.4
H-Index - 65
eISSN - 1099-0801
pISSN - 0269-3879
DOI - 10.1002/bmc.2777
Subject(s) - chemistry , chromatography , high performance liquid chromatography , in vivo , gradient elution , polyamine , pharmacology , biochemistry , medicine , biology , microbiology and biotechnology
A simple and sensitive method for the simultaneous determination of plasma concentrations of five polyamines in normal and Hepatoma‐22 mice, and mice treated with Mylabris and Acanthopanax senticosus was developed by HPLC‐ESI‐MS. Male Kunming mice were divided into nine groups, a control group (inoculation without treatment), a positive group (Cyclophosphamide), treatment groups [Mylabris (4, 8, 16 mg/kg), Acanthopanax senticosus (6, 12, 24 g/kg)] and a normal group (without inoculation). Twenty‐four hours after the last administration, plasma samples were collected. The derived polyamines were separated on a C 18 column by a gradient elution using methanol–water with excellent linearity within the range from 2.5 to 1000 ng/mL. Polyamines were confirmed as useful biochemical markers of hepatoma. The differences in anti‐cancer therapeutic efficacy between Mylabris and Acanthopanax senticosus might contribute to the variability of polyamine levels in vivo . This HPLC‐ESI‐MS method was successfully applied to investigate the relationship between polyamines and cancer in mice and might be a useful method to test the activity of potential anti‐tumor drugs. Copyright © 2012 John Wiley & Sons, Ltd.